On this page of StockholderLetter.com we present the latest annual shareholder letter from Nurix Therapeutics, Inc. — ticker symbol NRIX. Reading current and past NRIX letters to shareholders can bring important insights into the investment thesis.
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
 • shareholder letter icon 3/27/2024 Letter Continued (Full PDF)
 • stockholder letter icon More "Biotechnology" Category Stockholder Letters
 • Benford's Law Stocks icon NRIX Benford's Law Stock Score = 91


NRIX Shareholder/Stockholder Letter Transcript:


)0B78=6C>=            


  0A: !=4 
    '   $ "!$& "'$%'  & &! %  & !    !$   3  !  &   %  '$ &  %  *         & !    


 >A C74 58B20; H40A 4=343  >E4<14A       
&$  % & !  $ "!$& "'$%'  & &! %  & !    !$   3  !  &   %  '$ &  %  *         & !    


 ><<8BB8>=  8;4  D<14A          

  G02C =0<4 >5 $468BCA0=C 0B B?4285843 8= 8CB  70AC4A 

 4;0F0A4

 %C0C4 >A >C74A 9DA8B382C8>= >5
8=2>A?>A0C8>= >A >A60=8I0C8>= 
   $ %   H4A
 34=C85820C8>=  >  
    !F4=B %CA44C  %D8C4   
%0=  A0=28B2>    

  33A4BB >5 ?A8=28?0; 4G42DC8E4 >55824B 

 ,8?  >34 
$468BCA0=CKB C4;4?7>=4 =D<14A  8=2;D38=6 0A40 2>34   



%42DA8C84B A468BC4A43 ?DABD0=C C> %42C8>= 
 1  >5 C74  2C  
&A038=6
%H<1>; B 
(,#2
&8C;4 >5 4027 2;0BB
 FDDFE -KF:B  G8I M8CL<        G5 4027 4G270=64 >= F7827 
A468BC4A43
(8J;8H !CF98C '8IB@JK  F= K?<  :K  (FE<
#E;@:8K< 9P :?<:B D8IB @= K?< ,<>@JKI8EK @J 8 N@JKI8EK @J EFK I@JKI8EK      ?8J =@C<; 8CC I<  :K F=      
;LI@E> K?< GI<:<;@E>    DFEK?J  FI =FI JL:? J?FIK@JKI8EK N8J I 
I@JKI8EK ?8J JL9D@KK<; LC8K@FE - .  T        F= K?@J :?8GK K?< GI<:<;@E>    DFEK?J  FI =FI JL:? J?FIK@JKI8EK N8J I@JKI8EK @J 8 C8I>< 8:: :FDG8EP  FI 8E 
@E> >IFNK? :FDG8EP  -<< K?< ;<=@E@K@FEJ F= [C8I>< 8:: :FDG8EP \ 8E; [@E> >IFNK? 
:FDG8EP\ @E ,LC<   9   F= K?<  O:?8E><  :K  
&8I>< 8:: :FDG8EP

 D@E> >IFNK? :FDG8EP

#= 8E @E> >IFNK? :FDG8EP  @E;@:8K< 9P :?<:B D8IB @= K?< I<>@JKI8EK ?8J  N@K? 8EP E JK8E;8I;J GIFM@;<; GLIJL8EK KF -<:K@FE    8  F= K?<  O:?8E><  :K   
#= J<:LI@K@@JK@JKI8EK @E:CL;<; @E K?< 
=@C@E> I<=C<:K K?< :FII<:K@FE F= 8E @JKI8EK^J  K?< I@JKI8EK @J 8 J?<  :K   3@JKI8EK ?8J =@C<; 8 I LE;@JK =@ID K?8K 
GI>I<>8K< D8IB@JKI8EK  98J<; FE K?< :CFJ@E> GI@:< F= K?< ,<>@JKI8EK^J :FDDFE JKF:B FE 
'8P           K?< C8JK 9LJ@E@JKI8EK^J DFJK I<:@JKI8EK =FI 8EP FK?@JKI8EK ?8;            J?8I  
 ) /' (.- #( ),*), .    3 ,   , (  
 @JKI8EK^J ;<=@E@K@M< *IFOP -K8K@JKI8EK^J       EEL8C '< F= -KF:B?FC;<  FDD@JJ@FE GLIJL8EK KF ,<>LC8K@FE     N@K?@E     ;8PJ F= K?< ,<>@JKI8EK^J =@J:8C P<8I 
shareholder letter icon 3/27/2024 Letter Continued (Full PDF)
 

NRIX Stockholder/Shareholder Letter (Nurix Therapeutics, Inc.) | www.StockholderLetter.com
Copyright © 2023 - 2025, All Rights Reserved

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.